The prevalence of sleep-disordered breathing in Northwest Russia: The ARKHsleep study. (15th July 2020)

• Record Type: Journal Article
• Authors: Khokhrina, Anna; Andreeva, Elena; Degryse, Jean-Marie
• Is Part Of: Chronic respiratory disease. Volume 17(2020)
• Publication Date: 2020-07-15
• Subjects: Sleep-disordered breathing -- prevalence -- symptoms -- cardiovascular diseases; Respiratory organs -- Diseases -- Periodicals; 616.2005
• DOI: 10.1177/1479973120928103
• Languages: English
• ISSNs: 1479-9723

Abstract

Sleep-disordered breathing (SDB) is a chronic condition characterized by repeated breathing pauses during sleep. The reported prevalence of SDB in the general population has increased over time. Furthermore, in the literature, a distinction is made between SDB, obstructive sleep apnea (OSA), and "OSA syndrome" (OSAS). Patients with SDB are at increased risk of comorbid cardiovascular diseases (CVDs). The aim of the ARKHsleep study was to assess the prevalence of SDB in general and of OSA and OSAS in particular. A total of 1050 participants aged 30–70 years, who were randomly selected from a population register, were evaluated for the probability of SDB using the Epworth Sleepiness Scale score and body mass index. Sleep was recorded for one night via home sleep apnea testing (Somnolter®). Medical conditions were determined from medical records. Additional data included background characteristics, anthropometric variables, blood pressure, and scores from four questionnaires. The survey sample consisted of 41.2% males and had a mean age of 53.1 ± 11.3 years. The prevalence of mild-to-severe, moderate-to-severe, and severe SDB was 48.9% [45.8–51.9], 18.1% [15.9–20.6], and 4.5% [3.2–5.8], respectively. Individuals reporting snoring or breathing pauses had a higher severity of SDB than individuals free of symptoms. The ARKHsleep study revealed a high burden of both SDB and CVD; however, more large-scale cohort studies and intervention studies are needed to better understand whether the early recognition and treatment of mild SDB with or without symptoms will improve cardiovascular prognosis and/or quality of life.